Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study
Tài liệu tham khảo
Vargas-Serafin, 2021, Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting, Clin Lymphoma Myeloma Leuk, 21, 182, 10.1016/j.clml.2020.11.020
2020
Cifras y estimaciones de cáncer en el mundo Globocan e IARC. The Global Cancer Observatory 2018 [Internet]. 2018.
Estimated number of incident cases from 2018 to 2040, all cancers, both sexes, all ages Available at: https://gco.iarc.fr/tomorrow/graphic-bar? type=1&type_sex=0&mode=population&sex=0&populations=170&cancers=39&age_group=value&apc_male=0&apc_female=0&single_unit=500000&print=0#collapse-group-0-1: International Agency for Research of Cancer; 2020
DANE. Causas de muerte en el 2018 Available at: http://systema74.dane.gov.co/bincol/RpWebEngine.exe/Portal?BASE=DEFOC2018〈=esp:DANE; 2018
WHO classification of Tumors of Haematopoietic and Lymphoid Tissues 2017.
Arias, 2013, Registros poblacionales de cáncer: avances en Colombia, Chile y Brasil, Rev Fac Nac Salud Pública, 31, 128
Cancer IAfRi. Globocan Colombia 2020 Available at: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf: Organización Mundial de la Salud; 2020
Fondo Colombiano de Enfermedades de Alto Costo CdACC. Situación del cáncer en la pobla ción adulta atendida en el SGSSS de Colombia 2019. 2019.
Hungria, 2017, Observational study of multiple myeloma in Latin America, Ann Hematol, 96, 65, 10.1007/s00277-016-2866-9
Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, The Lancet Oncology, 15, E538, 10.1016/S1470-2045(14)70442-5
Greipp, 2005, International staging system for multiple myeloma, J Clin Oncol, 23, 3412, 10.1200/JCO.2005.04.242
Belotti, 2020, Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years, Am J Hematol, 95, 759, 10.1002/ajh.25797
Martínez, 2020, Multiple Myeloma Mortality Incidence Prevalence of Disease - Mmy Mind Study, Blood, 136, 10, 10.1182/blood-2020-142376
Moreau, 2016, VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial, Blood, 127, 2569, 10.1182/blood-2016-01-693580
Mai, 2015, Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma, Leukemia, 29, 1721, 10.1038/leu.2015.80
Kariyawasan, 2007, Multiple myeloma: Causes and consequences of delay in diagnosis, QJM, 100, 635, 10.1093/qjmed/hcm077
Curado, 2018, Epidemiology of multiple myeloma in 17 Latin American countries: An update, Cancer Medicine, 7, 2101, 10.1002/cam4.1347
Maiolino, 2018, Unmet needs in multiple myeloma in Brazil from physicians’ perspective – barriers in quality of life and disease management, Jornal Brasileiro de Economia da Saúde, 10, 165, 10.21115/JBES.v10.n2.p165-171
Ghalehsari, 2019, An institutional retrospective study on recognizing the delay in multiple myeloma diagnosis, Blood, 134, 3430, 10.1182/blood-2019-127625
Koshiaris, 2019, Methods for reducing delays in the diagnosis of multiple myeloma, International Journal of Hematologic Oncology, 8, 10.2217/ijh-2018-0014
Chng, 2014, IMWG consensus on risk stratification in multiple myeloma, Leukemia, 28, 269, 10.1038/leu.2013.247
Palumbo, 2015, Revised international staging system for multiple myeloma: a report from international myeloma working group, J Clin Oncol, 33, 2863, 10.1200/JCO.2015.61.2267
Cazaubiel, 2020, Risk and Response-Adapted Treatment in Multiple Myeloma, Cancers (Basel), 12, 3497, 10.3390/cancers12123497
Attal, 1997, Standard therapy versus autologous transplantation in multiple myeloma, Hematol Oncol Clin North Am, 11, 133, 10.1016/S0889-8588(05)70419-6
Child, 2003, High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma, N Engl J Med, 348, 1875, 10.1056/NEJMoa022340
Palumbo, 2014, Autologous transplantation and maintenance therapy in multiple myeloma, N Engl J Med, 371, 895, 10.1056/NEJMoa1402888
Attal, 2017, Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma, N Engl J Med, 376, 1311, 10.1056/NEJMoa1611750
Gay, 2017, Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis, Leukemia, 31, 1727, 10.1038/leu.2016.381
Riva, 2015, Real-World Data on Multiple Myeloma: A Prospective National Registry in Uruguay, Blood, 126, 5614, 10.1182/blood.V126.23.5614.5614
Mohty, 2018, Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, Clin Lymphoma Myeloma Leuk, 18, e401, 10.1016/j.clml.2018.06.018
Jaimovich, 2017, Latin America: the next region for haematopoietic transplant progress, Bone Marrow Transplant, 52, 671, 10.1038/bmt.2016.361
de Moraes Hungria, 2020, Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016, Br J Haematol, 188, 383, 10.1111/bjh.16124
Verelst, 2018, Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS), Hemasphere, 2, e45, 10.1097/HS9.0000000000000045